From the Cover: A unique basaltic micrometeorite expands the inventory of solar system planetary crusts

Micrometeorites with diameter ≈100–200 μm dominate the flux of extraterrestrial matter on Earth. The vast majority of micrometeorites are chemically, mineralogically, and isotopically related to carbonaceous chondrites, which amount to only 2.5% of meteorite falls. Here, we report the discovery of the first basaltic micrometeorite (MM40). This micrometeorite is unlike any other basalt known in the solar system as revealed by isotopic data, mineral chemistry, and trace element abundances. The discovery of a new basaltic asteroidal surface expands the solar system inventory of planetary crusts and underlines the importance of micrometeorites for sampling the asteroids'' surfaces in a way complementary to meteorites, mainly because they do not suffer dynamical biases as meteorites do. The parent asteroid of MM40 has undergone extensive metamorphism, which ended no earlier than 7.9 Myr after solar system formation. Numerical simulations of dust transport dynamics suggest that MM40 might originate from one of the recently discovered basaltic asteroids that are not members of the Vesta family. The ability to retrieve such a wealth of information from this tiny (a few micrograms) sample is auspicious some years before the launch of a Mars sample return mission.     

Fanconi anemia genes are highly expressed in primitive CD34<Superscript>+</Superscript>hematopoietic cells

Background  

Fanconi anemia (FA) is a complex recessive genetic disease characterized by progressive bone marrow failure (BM) and a predisposition to cancer. We have previously shown using the Fancc mouse model that the progressive BM failure results from a hematopoietic stem cell defect suggesting that function of the FA genes may reside in primitive hematopoietic stem cells.     

Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4

In the Goto-Kakizaki (GK) rat, a genetic model of type 2 diabetes, the neonatal beta-cell mass deficit is considered to be the primary defect leading to basal hyperglycemia, which is detectable for the first time 3 weeks after birth. We investigated in GK females the short- and the long-term effects of a treatment with glucagon-like peptide-1 (GLP-1) or its long-acting analog exendin-4 (Ex-4) during the first postnatal week (during the prediabetic period). GK rats were treated with daily injections of glucagon-like peptide-1 (400 microg x kg(-1) x day(-1)) or Ex-4 (3 microg x kg(-1) x day(-1)) from day 2 to day 6 after birth and were evaluated against Wistar and untreated GK rats. Under these conditions, on day 7 both treatments enhanced pancreatic insulin content and total beta-cell mass by stimulating beta-cell neogenesis and regeneration. Follow-up of biological characteristics from day 7 to adult age (2 months) showed that such a GLP-1 or Ex-4 treatment exerted long-term favorable influences on beta-cell mass and glycemic control at adult age. As compared to untreated GK rats, 2-month-old treated rats exhibited significantly decreased basal plasma glucose. Their glucose-stimulated insulin secretion, in vivo after intravenous glucose load or in vitro using isolated perfused pancreas, was slightly improved. This contributed at least partly to improve the in vivo plasma glucose disappearance rate, which was found to be increased in both treated GK groups compared to the untreated GK group. These findings in the GK model indicated, for the first time, that GLP-1 or Ex-4 treatment limited to the prediabetic period delays the installation and limits the severity of type 2 diabetes. Under these conditions, GLP-1 represents a unique tool because of its beta-cell replenishing effect in spontaneously diabetic rodents. It may prove to be an invaluable agent for the prevention of human type 2 diabetes.     

Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice

EM-652 exerts pure antiestrogenic activity in the mammary gland and endometrium, while tamoxifen, the antiestrogen most widely used for the treatment of breast cancer, exerts mixed antiestrogenic-estrogenic activity in these tissues. Our objective was to compare the agonistic and antagonistic effects of EM-652 with tamoxifen and 5 other antiestrogens on the growth of ZR-75-1 human breast xenografts in ovariectomized nude mice. During the 23 weeks of treatment at a daily oral dose of 50 microg, EM-652 was the only compound that decreased tumor size relative to pretreatment values, whereas the 6 other antiestrogens only decreased to various extents the progression rate stimulated by estrone. Under estrone stimulation, all groups of animals had more than 60% of their tumors in the progression category except for the EM-652-treated group, where only 7% of the tumors progressed. In the absence of estrone stimulation, progression was seen in 60%, 33%, 21% and 12% of tumors in the tamoxifen-, idoxifene-, toremifene- and raloxifene-treated groups, respectively, while only 4% of tumors progressed in the EM-652-treated group. The agonistic and antagonistic actions of each antiestrogen were also measured on endometrial epithelial cell thickness. Our present findings indicate that EM-652, in addition to being the most potent antiestrogen on human breast tumor growth, has no agonistic effect in breast and endometrial tissues. Since previous data have shown benefits of EM-652 on bone density and lipid profile, this compound could be an ideal candidate for chemoprevention of breast and uterine cancers, while protecting against osteoporosis and cardiovascular disease.     

Hydrodynamic contributions to multimodal guidance of prey capture behavior in fish

Water movements, of both abiotic and biotic origin, provide a wealth of information of direct relevance to the guidance of prey capture behavior. To gather hydrodynamic information, fish have sensors of two basic types: those scattered over the surface of the body known as superficial neuromasts and similar sensors embedded in subdermal lateral line canals. Recently, the anatomical dichotomy between superficial and canal neuromasts has been matched by demonstrations of a corresponding functional dichotomy. Prey detection and localization are evidently mediated by canal neuromasts, whereas superficial neuromasts are more sensitive to water flows over the surface of the fish and participate in the orientation to water currents, a behavior known as rheotaxis. However, rheotaxis in combination with chemosensory inputs can also guide fish to their prey. Thus there is evidence that both lateral line sub-modalities either alone or in concert with other senses play a role in prey capture. Are there circumstances where prey capture requires integration of information from both lateral line sub- modalities? Recent evidence shows that fish are capable of tracking other fish on the basis of the hydrodynamic trails left behind by their swimming motion. Pharmacological and physical ablation of lateral line end organs shows that indeed integration of information from both sub-modalities is required for the complex hydrodynamic task of natural prey capture in the dark. Furthermore, these experiments provide an excellent demonstration of the integration of hydrodynamic, chemosensory, tactile and visual information for the multimodal guidance of prey capture behavior.     

Dysphagia in multiple sclerosis

Objectives: (1) To determine the prevalence of swallowing problems in MS patients and its relation to the overall disability. (2) To define the most frequent symptoms suggestive of dysphagia. (3) To describe the abnormalities on manofluoroscopy (MFS). Methods: Three hundred and eight consecutive MS patients were asked whether they ever had swallowing problems. If so the questionnaire of the Johns Hopkins Swallowing Centre was applied to qualify the dysphagia. A MFS was performed in 30 patients with dysphagia covering the entire spectrum of MS. Overall disability was assessed using the Expanded Disability Status Scale (EDSS). Results: Seventy-three of our 309 patients had permanent dysphagia (24%). Another 5% had a history of transitory swallowing problems only. Permanent dysphagia started to be a problem in mildly impaired patients (EDSS 2–3). Prevalence increased together with rising disability to reach 65% in the most severely disabled subjects (EDSS 8–9). Two alarming symptoms of patients with swallowing problems, coughing or choking during the meal and a history of pneumonia were present in 59%, respectively, 12% of these patients. MFS showed deficiency of the oral phase in all patients, while only the patients with an EDSS higher than 7.5 showed abnormalities of the pharyngeal phase. Conclusions: Permanent dysphagia may already develop in mildly impaired MS patients but becomes a rather frequent finding in MS patients with moderate or severe disability. MFS is a sensitive and useful ancillary examination. Important qualitative changes of the pharyngeal phase on MFS are seen in patients with an EDSS higher than 7.5.     

HTLV-I negative tropical spastic paraparesis: a scientific challenge

We reviewed the historical, clinical and etiological aspects of the progressive chronic spastic myelopathies of unknown etiology, disserting on the clinical similarities between HTLV-I seropositive and seronegative tropical spastic paraparesis (TSP), as well as focusing on the PCR studies of the seronegative TSP.